Helix BioMedix Inc
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.
Helix BioMedix Inc (HXBM) - Total Assets
Latest total assets as of December 2013: $2.26 Million USD
Based on the latest financial reports, Helix BioMedix Inc (HXBM) holds total assets worth $2.26 Million USD as of December 2013.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Helix BioMedix Inc - Total Assets Trend (2000–2024)
This chart illustrates how Helix BioMedix Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Helix BioMedix Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Helix BioMedix Inc's total assets of $2.26 Million consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.4% |
| Accounts Receivable | $235.59K | 10.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Helix BioMedix Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Helix BioMedix Inc's current assets represent 99.5% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 84.4% of total assets in 2024, up from 44.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 54.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 10.7% of total assets.
Helix BioMedix Inc Competitors by Total Assets
Key competitors of Helix BioMedix Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Helix BioMedix Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Helix BioMedix Inc generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Helix BioMedix Inc is currently not profitable relative to its asset base.
Helix BioMedix Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.33 | 6.23 | 6.23 |
| Quick Ratio | 1.69 | 5.34 | 5.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $690.40K | $ 2.15 Million | $ 2.15 Million |
Helix BioMedix Inc - Advanced Valuation Insights
This section examines the relationship between Helix BioMedix Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.32 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -26.9% |
| Total Assets | $2.21 Million |
| Market Capitalization | $67.36K USD |
Valuation Analysis
Below Book Valuation: The market values Helix BioMedix Inc's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Helix BioMedix Inc's assets decreased by 26.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Helix BioMedix Inc (2000–2024)
The table below shows the annual total assets of Helix BioMedix Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.21 Million | -26.89% |
| 2023-12-31 | $3.03 Million | -23.03% |
| 2022-12-31 | $3.93 Million | -18.76% |
| 2021-12-31 | $4.84 Million | -14.25% |
| 2020-12-31 | $5.64 Million | +149.74% |
| 2013-12-31 | $2.26 Million | +99.03% |
| 2012-12-31 | $1.14 Million | -61.84% |
| 2011-12-31 | $2.97 Million | -43.11% |
| 2010-12-31 | $5.23 Million | +159.75% |
| 2009-12-31 | $2.01 Million | -25.55% |
| 2008-12-31 | $2.70 Million | +33.71% |
| 2007-12-31 | $2.02 Million | -33.79% |
| 2006-12-31 | $3.05 Million | -18.39% |
| 2005-12-31 | $3.74 Million | +30.52% |
| 2004-12-31 | $2.87 Million | -8.69% |
| 2003-12-31 | $3.14 Million | +44.04% |
| 2002-12-31 | $2.18 Million | +62.69% |
| 2001-12-31 | $1.34 Million | +22.71% |
| 2000-12-31 | $1.09 Million | -- |